Momenta Pharmaceuticals Stock Price

0.00 (0.0%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Momenta Pharmaceuticals Inc MNTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.00 0.0% 29.49 0.00 0.00 0.00 29.49 05:31:08
Bid Price Ask Price Spread Spread % News
29.80 39.40 9.60 24.37% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 29.49 USD

Momenta Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.47B 117.64M 70.14M $ 23.87M $ - -2.93 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Momenta Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MNTA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week30.0031.9828.4529.591,216,970-0.51-1.7%
1 Month32.6636.1728.4532.09900,321-3.17-9.71%
3 Months32.4639.8827.7033.551,157,326-2.97-9.15%
6 Months29.3139.8820.5331.131,127,6600.180.61%
1 Year11.4139.8811.0426.29962,89818.08158.46%
3 Years15.9039.889.5120.57760,07413.5985.47%
5 Years21.6839.887.8618.46701,5197.8136.02%

Momenta Pharmaceuticals Description

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.